Phio Pharmaceuticals Corp (PHIO) - Total Liabilities
Based on the latest financial reports, Phio Pharmaceuticals Corp (PHIO) has total liabilities worth $1.67 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Phio Pharmaceuticals Corp to assess how effectively this company generates cash.
Phio Pharmaceuticals Corp - Total Liabilities Trend (2011–2024)
This chart illustrates how Phio Pharmaceuticals Corp's total liabilities have evolved over time, based on quarterly financial data. Check PHIO cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Phio Pharmaceuticals Corp Competitors by Total Liabilities
The table below lists competitors of Phio Pharmaceuticals Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Fitzroy River Corporation Ltd
AU:FZR
|
Australia | AU$189.71K |
|
Big Pharma Split Corp Class A
TO:PRM
|
Canada | CA$12.62 Million |
|
Cannabist Company Holdings Inc
NEO:CBST
|
Canada | CA$710.75 Million |
|
Playtech Plc
LSE:PTEC
|
UK | GBX765.50 Million |
|
Rajshree Sugars & Chemicals Limited
NSE:RAJSREESUG
|
India | Rs4.08 Billion |
|
Duketon Mining Ltd
AU:DKM
|
Australia | AU$349.57K |
|
Siam Steel International Public Company Limited
BK:SIAM
|
Thailand | ฿738.17 Million |
|
Federal International Holdings Bhd
KLSE:8605
|
Malaysia | RM81.42 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Phio Pharmaceuticals Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Phio Pharmaceuticals Corp.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 22.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Phio Pharmaceuticals Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Phio Pharmaceuticals Corp (2011–2024)
The table below shows the annual total liabilities of Phio Pharmaceuticals Corp from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.01 Million | -37.88% |
| 2023-12-31 | $1.63 Million | -17.22% |
| 2022-12-31 | $1.97 Million | -39.04% |
| 2021-12-31 | $3.24 Million | +18.96% |
| 2020-12-31 | $2.72 Million | +18.81% |
| 2019-12-31 | $2.29 Million | +31.36% |
| 2018-12-31 | $1.74 Million | -23.00% |
| 2017-12-31 | $2.27 Million | -10.90% |
| 2016-12-31 | $2.54 Million | +12.03% |
| 2015-12-31 | $2.27 Million | -64.79% |
| 2014-12-31 | $6.44 Million | -35.53% |
| 2013-12-31 | $10.00 Million | -12.56% |
| 2012-12-31 | $11.43 Million | +401.18% |
| 2011-12-31 | $2.28 Million | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double posi… Read more